Takeda Exits Contrave Deal But Orexigen Insists Drug Can Grow
This article was originally published in PharmAsia News
Beware the Ides of March, especially if you're an investor in the obesity drug market. Orexigen added further evidence that the market is crumbling as it hitched its wagon to a partner that is even worse off.
Register for our free email digests: